Clinical focus Target glioblastoma and solid tumors with immuno-oncology platforms; leverage existing expertise of founders in virology and brain tumor therapy to position ISTARI as a specialized partner for CNS oncology opportunities and trials.

Early stage traction Clinical-stage with ongoing LUMINOS-103 basket trial and documented first patient dosing in NMIBC substudy; potential partners can co-develop or fund expansion into additional tumor indications and lines of therapy.

Strategic leadership Past leadership changes in commercial and medical affairs indicate a receptiveness to strong BD collaboration; identify opportunities to engage for accelerated trial startup, manufacturing scale-up, and potential advisory or sponsorship roles.

Manufacturing readiness Recent appointment of Chief Manufacturing Officer suggests focus on scalable production; sell-in manufacturing partnerships, process optimization services, or contract manufacturing to support trial expansion and commercialization plans.

IP and science leverage Publications on tumor microenvironment modulation and TBK1-IRF3 signaling underline a differentiated immunotherapy approach; offer collaboration on platform validation studies, translational biomarkers, and co-development of companion diagnostics.